Red Door picked to launch Bayer Vardenafil drug

Red Door Communications has been appointed by pharmaceutical giant

Bayer to handle PR for the pre-launch and launch of Vardenafil -

medication designed to improve erectile function.

The appointment, made following a three-way pitch, sees Red Door scoop

the account, which will run for an initial period of one year.

Bayer's in-house team will handle the campaign to gain European approval

for the drug, likely to be sought in 2002.

Red Door will then work alongside the manufacturer to 'prepare the

market' for the product's appearance in an increasingly competitive

sector, which has until now been dominated by the runaway success of

Viagra. The agency will then handle the product launch, providing the EU

sanctions the drug.

According to Red Door MD Catherine Warne, the agency will be 'working

with the client over the next couple of weeks on the positioning of the


Red Door will seek to address the stigma surrounding the ailment, which

sees many suffer in silence rather than seek medical assistance.

The account is headed by Red Door director Julia Tollis, reporting to

Kerry Cresswell, product manager for Vardenafil at Bayer.

'It is estimated that nearly half of all men over 40 in the UK will have

erection problems by the year 2010,' claimed Tollis.

'There is clearly a great and increasing need for effective treatment

that is suitable for a wide range of men,' she added.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in